keyword
MENU ▼
Read by QxMD icon Read
search

Preoperative chemotherapy of NSCLC

keyword
https://www.readbyqxmd.com/read/28621292/is-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-an-effective-diagnostic-procedure-in-restaging-of-non-small-cell-lung-cancer-patients
#1
Erdoğan Cetinkaya, Ozan Usluer, Aydın Yılmaz, Nuri Tutar, Ertan Çam, Mehmet Akif Özgül, Nilgün Yılmaz Demirci
BACKGROUND AND OBJECTIVES: Selecting the diagnostic procedure for mediastinal restaging after chemotherapy and/or radiotherapy in Stage IIIA-N2 non-small cell lung cancer (NSCLC) patients remains a problem. The aim of the study was to determine the efficacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the evaluation of mediastinal lymph nodes in the restaging of NSCLC patients. MATERIALS AND METHODS: The present multicentric study retrospectively analyzed the results of Stage IIIA-N2 NSCLC patients who had undergone EBUS for mediastinal restaging after preoperative chemotherapy or radiotherapy or both...
May 2017: Endoscopic Ultrasound
https://www.readbyqxmd.com/read/28550671/-analysis-of-prognostic-factors-for-patients-with-stage%C3%A2-b-non-small-cell-lung-cancer-after-operation
#2
P Song, R C Zang, M Y Zhang, L Liu, S G Gao
Objective: To study the prognostic factors for patients with stage ⅠB non-small cell lung cancer (NSCLC) after radical operation (R0). Methods: The clinical data of 458 patients who underwent radical resection for NSCLC and were pathologically diagnosed with stage ⅠB lung cancer from January 2009 to December 2010, were reviewed retrospectively. Those cases include 269 male patients and 189 female, aged between 28 and 88, with a median age of 61 years. The Kaplan-Meier method and Log rank test were used for univariate survival analysis and the Cox proportional hazards model for multivariate survival analysis...
April 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28523154/survival-rate-and-prognostic-factors-of-surgically-resected-clinically-synchronous-multiple-primary-non-small-cell-lung-cancer-and-further-differentiation-from-intrapulmonary-metastasis
#3
Fei Xiao, Deruo Liu, Yongqing Guo, Bin Shi, Zhiyi Song, Yanchu Tian, Zhenrong Zhang, Chaoyang Liang
BACKGROUND: The diagnosis, staging, and therapeutic strategy for synchronous multiple primary non-small cell lung cancer (SMP-NSCLC) remain unclear. Distinguishing SMP-NSCLC from intrapulmonary metastasis is difficult but of great importance for selecting the surgical procedure and prognoses. METHODS: Fifty-two patients diagnosed with SMP-NSCLC according to the modified Martini-Melamed criteria in the thoracic surgery department of the China-Japan Friendship Hospital from November 2004 to December 2015 were enrolled in this retrospective study...
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28426673/lymph-node-volume-predicts-survival-but-not-nodal-clearance-in-stage-iiia-iiib-nsclc
#4
Vishesh Agrawal, Thibaud P Coroller, Ying Hou, Stephanie W Lee, John L Romano, Elizabeth H Baldini, Aileen B Chen, David Kozono, Scott J Swanson, Jon O Wee, Hugo J W L Aerts, Raymond H Mak
BACKGROUND: Locally advanced non-small cell lung cancer (LA-NSCLC) patients have poorer survival and local control with mediastinal node (N2) tumor involvement at resection. Earlier assessment of nodal burden could inform clinical decision-making prior to surgery. This study evaluated the association between clinical outcomes and lymph node volume before and after neoadjuvant therapy. MATERIALS AND METHODS: CT imaging of patients with operable LA-NSCLC treated with chemoradiation and surgical resection was assessed...
2017: PloS One
https://www.readbyqxmd.com/read/28403675/advances-in-the-use-of-surgery-and-multimodality-treatment-for-n2-non-small-cell-lung-cancer
#5
REVIEW
Paul E Van Schil, Krishan Yogeswaran, Jeroen M Hendriks, Patrick Lauwers, Corinne Faivre-Finn
Stage IIIA-N2 non-small cell lung cancer (NSCLC) represents a heterogeneous group of bronchogenic carcinomas with locoregional involvement. Different categories of N2 disease exist, ranging from unexpectedly encountered N2 involvement after detailed preoperative staging or 'surprise' N2, to potentially resectable disease treated within a combined modality setting, and finally, bulky N2 involvement treated by chemoradiation. Areas covered: Large randomised controlled trials and meta-analyses on stage IIIA-N2 NSCLC have been published but their implications for treatment remain a matter of debate...
June 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28364180/combined-small-cell-lung-carcinoma-and-giant-cell-carcinoma-a-case-report
#6
Tomohito Saito, Koji Tsuta, Kento J Fukumoto, Hiroshi Matsui, Toshifumi Konobu, Yoshitaro Torii, Takashi Yokoi, Takayasu Kurata, Hiroaki Kurokawa, Yoshiko Uemura, Yukihito Saito, Tomohiro Murakawa
BACKGROUND: Combined small cell lung carcinoma (SCLC) is defined as SCLC combined with elements of non-small cell lung carcinoma (NSCLC), accounting for approximately 30% of cases of SCLC. However, combined SCLC and giant cell carcinoma (GC) is very rare. CASE PRESENTATION: A 50-year-old woman with a 45 pack-year smoking history was referred to our hospital for further investigation of an abnormal left hilar shadow. Chest computed tomography (CT) revealed a 28-mm solid pulmonary nodule in the left lower lobe and an enlarged left hilar lymph node adjacent to the left main pulmonary artery...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28228221/-efficacy-and-potential-application-of-neoadjuvant-chemotherapy-in-patients-with-iiia-stage-non-small-cell-lung-cancer
#7
Cuiping Tang, Si Qin, Wanchun Wu, Yang Wu, Tao Zhang
BACKGROUND: The therapeutic effect and side effect of neoadjuvant chemotherapy were still disputing issues when applied to resectable IIIa stage non-small cell lung cancer (NSCLC) patients. The retrospective analysis was aimed to investigate the short-term efficacy and postoperative complications in resectable IIIa NSCLC patients treated with neoadjuvant chemotherapy. METHODS: According to inclusion criteria and exclusion criteria, 370 patients with clinical diagnosis of IIIa NSCLC were selected from our hospital between January 2011 and October 2013 were retrospectively analyzed...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28215851/a-novel-neoadjuvant-therapy-for-operable-locally-invasive-non-small-cell-lung-cancer-phase-i-study-of-neoadjuvant-stereotactic-body-radiotherapy-linnearre-i-nct02433574
#8
Nhu-Tram A Nguyen, Naghmeh Isfahanian, Gregory Pond, Wael Hanna, Jean-Claude Cutz, James Wright, Anand Swaminath, Yaron Shargall, Tom Chow, Marcin Wierzbicki, Gordon Okawara, Kimmen Quan, Christian Finley, Rosalyn Juergens, Theodoros Tsakiridis
BACKGROUND: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined...
January 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27912893/-perioperative-therapies-in-surgical-non-n2%C3%A2-non-small-cell-lung-cancer
#9
REVIEW
Anne-Marie Ruppert, Armelle Lavolé, Jalal Assouad, Jacques Cadranel, Marie Wislez
Platinum-based perioperative chemotherapy is actually the standard of care in stage II-IIIa non-small cell lung cancer (NSCLC). A benefit may also be seen in stage IB NSCLC with tumors of more than 4cm of diameter. Perioperative chemotherapy improves 5-year survival of 4 to 15%. This benefit is mainly proved by postoperative chemotherapy trials. Nevertheless, preoperative chemotherapy has advantages: a better tolerance, an estimation of tumor chemosensibility, without an increased postoperative morbimortality...
January 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/27863731/pulmonary-resection-for-synchronous-m1b-cstage-iv-non-small-cell-lung-cancer%C3%A2-patients
#10
Masafumi Yamaguchi, Makoto Edagawa, Yuzo Suzuki, Ryo Toyozawa, Fumihiko Hirai, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
BACKGROUND: We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion. METHODS: Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed. RESULTS: Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years)...
May 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27794400/pre-and-postoperative-care-for-stage-i-iii-nsclc-which-quality-of-care-indicators-are-evidence-based
#11
REVIEW
Rachel C Numan, Martijn Ten Berge, Jacobus A Burgers, Houke M Klomp, Johanna W van Sandick, Paul Baas, Michel W Wouters
Identification of evidenced-based Quality of Care (QoC) indicators for lung cancer care is essential to quality improvement. The aim of this review was to identify evidence-based quality indicators for the pre- and postoperative care of stage I-III Non Small Cell Lung Cancer (NSCLC) provided by the lung physician. To obtain these indicators, a search in PubMed, Embase and the Cochrane library database was performed. English literature published between 1980 and 2012 was included and search terms regarding 'lung neoplasms', 'quality of care', 'pathology', 'diagnostic methods', 'preoperative and postoperative treatment' were used...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27677242/neoadjuvant-chemoradiotherapy-vesus-chemotherapy-alone-followed-by-surgery-for-resectable-stage-iii-non-small-cell-lung-cancer-a-meta-analysis
#12
Shan Xian Guo, Yan Jian, Ying Lan Chen, Yun Cai, Qing Yuan Zhang, Fang Fang Tou
Neoadjuvant Chemotherapy has been used for the stage III of non-small cell lung cancer (NSCLC) and has shown good clinical effects. However, the survival benefits of radiation therapy added in induction regimens remains controversial. We therefore conducted a meta-analysis of the published clinical trials to quantitatively evaluate the benefit of preoperative chemoradiotherapy. After searching the database of Pubmed, CNKI, EMBASE, ESMO, The Cochrane Library databases, The American Society of Clinical Oncology and Clinical Trials...
September 28, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27453414/high-preoperative-and-postoperative-levels-of-carcinoembryonic-antigen-and-cyfra-21-1-indicate-poor-prognosis-in-patients-with-pathological-stage-i-nonsmall-cell-lung-cancer
#13
X Duan, Y Cui, H Li, G Shi, B Wu, M Liu, D Chang, T Wang, Y Kong
BACKGROUND: Serum carcinoembryonic antigen (CEA) and the soluble fragment of cytokeratin 19 (CYFRA 21-1) are supposed to have a prognostic role in patients with nonsmall cell lung cancer (NSCLC) after surgery, but it has not been used as an adjunct to the tumor-node-metastasis (TNM) staging system to provide therapy options for patients with pathological Stage I NSCLC. This study was designed to investigate the effect of serum levels of CEA and CYFRA 21-1 before and after surgery on the prognosis of patients with Stage I NSCLC...
December 2015: Indian Journal of Cancer
https://www.readbyqxmd.com/read/27380644/psf1-partner-of-sld-five-1-is-a-prognostic-biomarker-in-patients-with-non-small-cell-lung-cancer-treated-with-surgery-following-preoperative-chemotherapy-or-chemoradiotherapy
#14
Ryu Kanzaki, Hisamichi Naito, Kazuyoshi Kise, Kazuhiro Takara, Daisuke Eino, Masato Minami, Yasushi Shintani, Soichiro Funaki, Tomohiro Kawamura, Toru Kimura, Meinoshin Okumura, Nobuyuki Takakura
BACKGROUND: PSF1 (Partner of SLD Five 1) is an evolutionarily conserved DNA replication factor that is part of the GINS (Go, Ichi, Nii, and San) complex . The objective of this study was to evaluate the relationship between PSF1 expression and prognosis in patients with non-small cell lung cancer (NSCLC) treated with surgery following preoperative chemotherapy or chemoradiotherapy. METHODS: Sixty-nine patients with NSCLC treated with surgery following preoperative chemotherapy or chemoradiotherapy who did not achieve pathologic complete response were enrolled...
November 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27261916/neoadjuvant-therapy-in-non-small-cell-lung-cancer
#15
REVIEW
Yifan Zheng, Michael T Jaklitsch, Raphael Bueno
Locally advanced (stage IIIA) non-small cell lung cancer (NSCLC) is confined to the chest, but requires more than surgery to maximize cure. Therapy given preoperatively is termed neoadjuvant, whereas postoperative therapy is termed adjuvant. Trimodality therapy (chemotherapy, radiation, and surgery) has become the standard treatment regimen for resectable, locally advanced NSCLC. During the past 2 decades, several prospective, randomized, and nonrandomized studies have explored various regimens for preoperative treatment of NSCLC...
July 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27118646/-analysis-of-the-role-of-pet-ct-suvmax-in-prognosis-and-its-correlation-with-%C3%A2-clinicopathological-characteristics-in-resectable-lung-squamous-cell-carcinoma
#16
Hongliang Ren, Wengui Xu, Jian You, Xiuyu Song, Hui Huang, Ning Zhao, Xiubao Ren, Xinwei Zhang
BACKGROUND: Lung cancer is the leading cause of cancer death in men and women in the world, more than one-half of cases are diagnosed at a advanced stage, and the overall 5-year survival rate for lung cancer is 18%. Lung cancer is divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Approximately 80%-85% of cases are NSCLC which includes three main types: adenocarcinoma (40%), squamous cell carcinoma (SCC) (20%-30%), and large cell carcinoma (10%). Although therapies that target driver mutations in adenocarcinomas are showing some promise, they are proving ineffective in smoking-related SCC...
April 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27035568/-neoadjuvant-radiochemotherapy-followed-by-curative-resection-in-patients-with-advanced-non-small-cell-lung-cancer-in-stage-iiia-iiib-prognostic-factors-and-results
#17
W Schreiner, W Dudek, S Lettmaier, S Gavrychenkova, R Rieker, R Fietkau, H Sirbu
The role of surgical lung resection following neo-adjuvant radio-chemotherapy (RCT) in patients with locally advanced non-small cell lung cancer (NSCLC) is yet not clearly defined. The aim of our study was to analyze the postoperative survival and to identify relevant prognostic factors. 46 patients underwent curative resections after neo-adjuvant RCT for locally advanced NSCLC (IIIA/IIIB) between February 2008 and February 2015. A retrospective data analysis regarding preoperative regression status, perioperative mortality, postoperative survival, patho-histological remission, relapse pattern and other prognostic factors was performed...
June 2016: Zentralblatt Für Chirurgie
https://www.readbyqxmd.com/read/26816105/prognostic-factors-and-long-term-survival-in-surgically-treated-brain-metastases-from-non-small-cell-lung-cancer
#18
Frederik Enders, Christoph Geisenberger, Christine Jungk, Justo Lorenzo Bermejo, Rolf Warta, Andreas von Deimling, Christel Herold-Mende, Andreas Unterberg
OBJECTIVE: Brain metastases (BMs) are the most common malignant brain tumors in adults. Despite multimodal treatment options such as microsurgery, radiotherapy and chemotherapy, prognosis still remains very poor. Non-small cell lung cancer (NSCLC) constitutes the most common source of brain metastases. In this study, prognostic factors in this patient population were identified through an in-depth analysis of clinical parameters of patients with BMs from NSCLC. PATIENTS AND METHODS: Clinical data of 114 NSCLC cancer patients who underwent surgery for BMs at the University Hospital Heidelberg were retrospectively reviewed for age, gender, type of treatment, time course of the disease, presence of neurologic symptoms, Karnofsky Performance Status (KPS), smoking history, presence of extracranial metastases at initial diagnosis of NSCLC, number, location and size of brain metastases...
March 2016: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/26782692/risk-factors-associated-with-recurrence-of-surgically-resected-node-positive-non-small-cell-lung-cancer
#19
Yoichi Ohtaki, Kimihiro Shimizu, Kyoichi Kaira, Toshiteru Nagashima, Kai Obayashi, Seshiru Nakazawa, Seiichi Kakegawa, Hitoshi Igai, Mitsuhiro Kamiyoshihara, Masahiko Nishiyama, Izumi Takeyoshi
PURPOSE: The aim of this study was to identify risk factors for recurrence in non-small cell lung cancer (NSCLC) patients with lymph node metastases after surgical resection. METHODS: We reviewed 66 consecutive patients with surgically resected NSCLC who had pathologically proven positive lymph nodes (pN1 or pN2). All patients underwent a preoperative 2-[(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) evaluation. We analyzed the recurrence-free survival (RFS) and recurrence-free proportion (RFP) according to the clinicopathological factors...
October 2016: Surgery Today
https://www.readbyqxmd.com/read/26586194/surgical-results-of-metastatic-spinal-cord-compression-mscc-from-non-small-cell-lung-cancer-nsclc-analysis-of-functional-outcome-survival-time-and-complication
#20
Se-Jun Park, Chong-Suh Lee, Sung-Soo Chung
BACKGROUND CONTEXT: A number of studies have reported favorable surgical results for metastatic spinal tumors from various solid tumors. However, there are few data available on metastatic spinal cord compression (MSCC) from lung cancer despite its considerable frequency. PURPOSE: The study aims to present the functional outcomes, survival time, and complications after surgical treatment for MSCC from non-small cell lung cancer (NSCLC). STUDY DESIGN/SETTING: This is a longitudinal observational study...
March 2016: Spine Journal: Official Journal of the North American Spine Society
keyword
keyword
52839
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"